PT  - JOURNAL ARTICLE
AU  - Rudolf A. Werner
AU  - Ralph A. Bundschuh
AU  - Lena Bundschuh
AU  - Stefano Fanti
AU  - Mehrbod S. Javadi
AU  - Takahiro Higuchi
AU  - Alexander Weich
AU  - Kenneth J. Pienta
AU  - Andreas K. Buck
AU  - Martin G. Pomper
AU  - Michael A. Gorin
AU  - Ken Herrmann
AU  - Constantin Lapa
AU  - Steven P. Rowe
TI  - Novel Structured Reporting Systems for Theranostic Radiotracers
AID  - 10.2967/jnumed.118.223537
DP  - 2019 May 01
TA  - Journal of Nuclear Medicine
PG  - 577--584
VI  - 60
IP  - 5
4099  - http://jnm.snmjournals.org/content/60/5/577.short
4100  - http://jnm.snmjournals.org/content/60/5/577.full
SO  - J Nucl Med2019 May 01; 60
AB  - Standardized reporting is more and more routinely implemented in clinical practice, and such structured reports have a major impact on a large variety of medical fields, such as laboratory medicine, pathology, and, recently, radiology. Notably, the field of nuclear medicine is constantly evolving as novel radiotracers for numerous clinical applications are developed. Thus, framework systems for standardized reporting in this field may increase clinical acceptance of new radiotracers, allow for inter- and intracenter comparisons for quality assurance, and be used in global multicenter studies to ensure comparable results and enable efficient data abstraction. In the last couple of years, several standardized framework systems for PET radiotracers with potential theranostic applications have been proposed. These include systems for prostate-specific membrane antigen–targeted PET agents to diagnose and treat prostate cancer, and systems for somatostatin receptor–targeted PET agents to diagnose and treat neuroendocrine neoplasia. In the present review, the framework systems for these 2 types of cancer will be briefly introduced, followed by an overview of their advantages and limitations. In addition, potential applications will be defined, approaches to validate such concepts will be proposed, and future perspectives will be discussed.